GLP-1: physiological effects and potential therapeutic applications
| Autor: | Kasper Aaboe, Jens J. Holst, Thure Krarup, Sten Madsbad |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
endocrine system
medicine.medical_specialty Endocrinology Diabetes and Metabolism Incretin Type 2 diabetes Satiety Response Glucagon-Like Peptide-1 Receptor Dipeptidyl peptidase Islets of Langerhans Endocrinology Glucagon-Like Peptide 1 Internal medicine Diabetes mellitus Weight Loss Receptors Glucagon Internal Medicine medicine Animals Humans Hypoglycemic Agents Dipeptidyl peptidase-4 Dipeptidyl-Peptidase IV Inhibitors Type 1 diabetes business.industry digestive oral and skin physiology Glucagon medicine.disease Glucagon-like peptide-1 Diabetes Mellitus Type 2 Animal studies business hormones hormone substitutes and hormone antagonists |
| Zdroj: | Diabetes, Obesity and Metabolism. 10:994-1003 |
| ISSN: | 1463-1326 1462-8902 |
| DOI: | 10.1111/j.1463-1326.2008.00853.x |
| Popis: | Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone with the potential to change diabetes. The physiological effects of GLP-1 are multiple, and many seem to ameliorate the different conditions defining the diverse physiopathology seen in type 2 diabetes. In animal studies, GLP-1 stimulates beta-cell proliferation and neogenesis and inhibits beta-cell apoptosis. In humans, GLP-1 stimulates insulin secretion and inhibits glucagon and gastrointestinal secretions and motility. It enhances satiety and reduces food intake and has beneficial effects on cardiovascular function and endothelial dysfunction. Enhancing incretin action for therapeutic use includes GLP-1 receptor agonists resistant to degradation (incretin mimetics) and dipeptidyl peptidase (DPP)-4 inhibitors. In clinical trials with type 2 diabetic patients on various oral antidiabetic regimes, both treatment modalities efficaciously improve glycaemic control and beta-cell function. Whereas the incretin mimetics induce weight loss, the DPP-4 inhibitors are considered weight neutral. In type 1 diabetes, treatment with GLP-1 shows promising effects. However, several areas need clinical confirmation: the durability of the weight loss, the ability to preserve functional beta-cell mass and the applicability in other than type 2 diabetes. As such, long-term studies and studies with cardiovascular end-points are needed to confirm the true benefits of these new classes of antidiabetic drugs in the treatment of diabetes mellitus. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text